Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
NovaBridge Biosciences ( (NBP) ) has provided an announcement.
On March 16, 2026, NovaBridge Biosciences reported that a recent U.S. Food and Drug Administration Type B meeting confirmed the potential eligibility of its lead oncology asset, givastomig, for an accelerated approval pathway in first-line Her2-negative, Claudin 18.2-positive, PD-L1-positive gastroesophageal cancer. The bispecific Claudin 18.2 x 4-1BB antibody is being developed in partnership with ABL Bio, with NovaBridge holding shared worldwide rights outside Greater China and South Korea.
The FDA feedback, grounded in positive Phase 1b combination data showing a 75% objective response rate, durable progression-free survival and favorable tolerability, clears the way for NovaBridge to launch a registrational Phase 3 immunochemotherapy combination trial as early as the fourth quarter of 2026 using objective response rate as the primary endpoint. This regulatory milestone strengthens NovaBridge’s competitive positioning in the emerging Claudin 18.2 gastric cancer segment and underscores the strategic importance of givastomig within its broader oncology and retinal disease pipeline, potentially accelerating the timeline to market access if later-stage data remain supportive.
The most recent analyst rating on (NBP) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on NovaBridge Biosciences stock, see the NBP Stock Forecast page.
Spark’s Take on NBP Stock
According to Spark, TipRanks’ AI Analyst, NBP is a Neutral.
The score is primarily held back by deteriorated financial performance (no 2024 revenue, persistent losses, and ongoing cash burn) despite low leverage. Technicals are mildly bearish with price below key moving averages and a slightly negative MACD, while valuation is largely neutral because negative earnings make the P/E less informative and no dividend support is shown.
To see Spark’s full report on NBP stock, click here.
More about NovaBridge Biosciences
NovaBridge Biosciences (Nasdaq: NBP) is a global biotechnology platform company focused on accelerating access to innovative medicines in oncology and ophthalmology. Its pipeline is led by givastomig, a Claudin 18.2 x 4-1BB bispecific antibody for Claudin 18.2-positive gastric and other gastrointestinal cancers, and VIS-101, a dual VEGF-A x ANG-2 inhibitor for retinal vascular diseases such as wet age-related macular degeneration and diabetic macular edema.
The company also develops ragistomig, a bispecific PD-L1 x 4-1BB antibody for solid tumors, and uliledlimab, an anti-CD73 antibody targeting adenosine-driven immunosuppression in cancer. VIS-101 has completed a randomized, dose-ranging Phase 2a study in wet AMD, with a Phase 2b trial planned for the second half of 2026, while NovaBridge maintains key global rights to these assets through partnerships and majority ownership of Visara, Inc.
Average Trading Volume: 746,614
Technical Sentiment Signal: Sell
Current Market Cap: $326.3M
For an in-depth examination of NBP stock, go to TipRanks’ Overview page.